Faulty Reagent Caused 'Marginal' Over-Reporting of Breast Cancer Recurrence With MammaPrint
April 14, 2010
Faulty Reagent Caused 'Marginal' Over-Reporting of Breast Cancer Recurrence With MammaPrint
An Agendia official said that the company has provided "new, corrected MammaPrint reports" for all of the physicians who received faulty results and has also implemented internal quality-control measures to guard against a similar issue in the future.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- FDA Provides Notice on Agendia's Ongoing MammaPrint Recall
May 19, 2010 / Pharmacogenomics Reporter - Agendia to Offer FFPE Sample Analysis for Symphony Suite of Breast Cancer Diagnostics
December 21, 2011 / Pharmacogenomics Reporter - Agendia Moving to Larger Lab to Keep Pace with Growing MammaPrint Testing Volume
August 11, 2010 / Pharmacogenomics Reporter - Clarient's Mammostrat to Enter Breast Cancer Recurrence Market as LDT by Fourth Quarter
July 14, 2010 / Pharmacogenomics Reporter - Ahead of FDA Meeting on LDTs, Test Developers Prep for Increased Oversight, but Greater Clarity
July 7, 2010 / Pharmacogenomics Reporter